Proteomics for development of vaccine

Adamczyk-Popławska, Monika; Markowicz, Sergiusz; Jagusztyn-Krynicka, Elżbieta Katarzyna

doi:10.1016/j.jprot.2011.01.019

Cited by 47 publications

(41 citation statements)

References 200 publications

(221 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bacterial Strains and Growth Conditions-The following N. gonorrhoeae strains were used in this study: FA1090 (22), MS11 (23), 1291 (24), F62 (25), FA19 (26), the clinical isolates LGB1, LG14, LG20, and LG26, which were collected from two public health clinics in Baltimore from 1991 to 1994 and differ in porB variable region type and pulsed gel electrophoresis patterns (21,27), 13 isolates from patients attending the Public Health-Seattle & King County Sexually Transmitted Disease clinic from 2011 to 2013 (supplemental Table S1), and the WHO 2015 reference strains (10,28,29).…”

Section: Methodsmentioning

confidence: 99%

“…Pioneered by Rappuoli and colleagues, reverse vaccinology-which initially included genome and later proteome mining-has proven to be very successful in the discovery of vaccine candidates against many pathogenic bacteria (12)(13)(14)(15). In particular, these methodologies paved the way for the newly developed group B meningococcal vaccine, which was a formidable effort for many years.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea

Zielke

Wierzbicki

Baarda

et al. 2016

Molecular & Cellular Proteomics

178

View full text Add to dashboard Cite

Expanding efforts to develop preventive gonorrhea vaccines is critical because of the dire possibility of untreatable gonococcal infections. Reverse vaccinology, which includes genome and proteome mining, has proven very successful in the discovery of vaccine candidates against many pathogenic bacteria. However, progress with this approach for a gonorrhea vaccine remains in its infancy. Accordingly, we applied a comprehensive proteomic platform-isobaric tagging for absolute quantification coupled with two-dimensional liquid chromatography and mass spectrometry-to identify potential gonococcal vaccine antigens. Our previous analyses focused on cell envelopes and naturally released membrane vesicles derived from four different Neisseria gonorrhoeae strains. Here, we extended these studies to identify cell envelope proteins of N. gonorrhoeae that are ubiquitously expressed and specifically induced by physiologically relevant environmental stimuli: oxygen availability, iron deprivation, and the presence of human serum. Together, these studies enabled the identification of numerous potential gonorrhea vaccine targets. Initial characterization of five novel vaccine candidate antigens that were ubiquitously expressed under these different growth conditions demonstrated that homologs of BamA (NGO1801), LptD (NGO1715), and TamA (NGO1956), and two uncharacterized proteins, NGO2054 and NGO2139, were surface exposed, secreted via naturally released membrane vesicles, and elicited bactericidal antibodies that cross-reacted with a panel of temporally and geographically diverse isolates. In addition, analysis of polymorphisms at the nucleotide and amino acid levels showed that these vaccine candidates are highly conserved among N. gonorrhoeae strains. Finally, depletion of BamA caused a loss of N. gonorrhoeae viability, suggesting it may be an essential target. Together, our data strongly support the use of proteomics-driven discovery of potential vaccine targets as a sound approach for identifying promising gonococcal antigens. Molecular & Cellular

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea

Zielke

Wierzbicki

Baarda

et al. 2016

Molecular & Cellular Proteomics

178

View full text Add to dashboard Cite

show abstract

“…And the other way to enhance and/or modulate the host immune response is to deliver a vaccine with an appropriate adjuvant. The tremendous progress of proteomics during the past few years has contributed to every successive stage of antigen characterization (Adamczyk-Poplawska et al 2011).…”

Section: Discussionmentioning

confidence: 99%

Analytical Control Strategy of Bacterial Subunit Vaccines

Lee¹,

Turula

Powell³

et al. 2014

Vaccine Analysis: Strategies, Principles, and Control

View full text Add to dashboard Cite

“…Advanced proteomic technologies are currently employed to facilitate identification of changes in proteome accompanying tumorigenesis. Mapping of the protein and peptide spectra and comparison of proteomic profiles between tumorous and adjacent nontumorous tissue samples are currently implemented in the search for novel biomarkers with improved specificities for diagnosis, prognosis and treatment monitoring [91].…”

Section: Vaccine Developmentsmentioning

confidence: 99%

Multi-dimensional Electrophoresis: The March in Pharma Applications

Shegokar

Sawant

2014

Nanoparticles' Promises and Risks

View full text Add to dashboard Cite

Electrophoresis is widely used in pharmaceutical field for multiple applications. It is mainly employed for protein separation and identification. The information obtained on protein content and composition from multiple gel electrophoresis provides basic knowledge required for drug design, biomarker, vaccine, and antibiotic research. Furthermore, combination with advance analytical techniques like MALDI-TOF, mass spectroscopy provides added advantages in analysing protien samples. Electrophoresis by single and multiple dimensional methods is becoming very popular in nanoparticle research to identify protein corona around particle which can predict organ targeting when used in vivo. This technique can also be used to detect toxicity potential of nanoparticles and generated oxidative stress. Multi-dimensional electrophoresis has already been used in conventional pharmaceutical application and now is marching to nanoparticle and/drug delivery research area.

show abstract

Proteomics for development of vaccine

Cited by 47 publications

References 200 publications

Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea

Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea

Analytical Control Strategy of Bacterial Subunit Vaccines

Multi-dimensional Electrophoresis: The March in Pharma Applications

Contact Info

Product

Resources

About